Trial record 1 of 1 for:
SOCRATES-REDUCED
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01951625 |
|
Recruitment Status :
Completed
First Posted : September 26, 2013
Results First Posted : March 25, 2021
Last Update Posted : March 25, 2021
|
Sponsor:
Bayer
Information provided by (Responsible Party):
Bayer
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard therapy for heart failure with reduced ejection fraction (HFrEF).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Heart Failure | Drug: Vericiguat (BAY1021189) (1.25 mg) Drug: Vericiguat (BAY1021189) (5 mg) Drug: Placebo | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 456 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure With Reduced Ejection Fraction (HFrEF) |
| Actual Study Start Date : | November 29, 2013 |
| Actual Primary Completion Date : | May 14, 2015 |
| Actual Study Completion Date : | June 9, 2015 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Heart Failure
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Vericiguat (BAY1021189) (10 mg)
2.5 mg orally once daily for 2 weeks, up-titration to 5 mg orally once daily for 2 weeks, up-titration to 10 mg orally once daily for 8 weeks
|
Drug: Vericiguat (BAY1021189) (1.25 mg)
1.25 mg BAY1021189 tablets Drug: Vericiguat (BAY1021189) (5 mg) 5 mg BAY1021189 tablets |
|
Experimental: Vericiguat (BAY1021189) (5 mg)
2.5 mg orally once daily for 2 weeks, then 5 mg orally once daily for 10 weeks (with sham titration)
|
Drug: Vericiguat (BAY1021189) (1.25 mg)
1.25 mg BAY1021189 tablets Drug: Vericiguat (BAY1021189) (5 mg) 5 mg BAY1021189 tablets |
|
Experimental: Vericiguat (BAY1021189) (2.5 mg)
2.5 mg orally once daily for 12 weeks (with sham titrations)
|
Drug: Vericiguat (BAY1021189) (1.25 mg)
1.25 mg BAY1021189 tablets |
|
Experimental: Vericiguat (BAY1021189) (1.25 mg)
1.25 mg orally once daily for 12 weeks (with sham titrations)
|
Drug: Vericiguat (BAY1021189) (1.25 mg)
1.25 mg BAY1021189 tablets |
|
Placebo Comparator: Placebo
Orally once daily for 12 weeks (with sham titrations)
|
Drug: Placebo |
Primary Outcome Measures :
- Change From Baseline in Log-Transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) to Week 12 [ Time Frame: Baseline, Week 12 ]Log-Transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) is a circulating plasma biomarker of cardiovascular function and prognosis in heart failure.
Other Outcome Measures:
- Changes in Heart Function as Measured by Echocardiography, Left Ventricular End-Diastolic Volume (LVEDV), and Left Ventricular End-Systolic Volume (LVESV) From Baseline to Week 12 [ Time Frame: Baseline, Week 12 ]Left Ventricular End-Diastolic Volume (LVEDV) and Left ventricular end-systolic volume (LVESV) are measured echocardiography parameter. These are acquired during a non-invasive echocardiography examination.
- Changes in Heart Function as Measured by Echocardiography, Left Ventricular Ejection Fraction (LVEF), From Baseline to Week 12 [ Time Frame: Baseline, Week 12 ]The left ventricular ejection fraction work index (LVEF) is a calculated echocardiography parameter. LVEF is derived from the directly measured parameters left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV). These 2 parameters are acquired during a noninvasive echocardiography examination. Formula: LVEF = 100*(LVEDV - LVESV)/LVEDV.
- Change From Baseline in Systolic and Diastolic Blood Pressure to Week 12 [ Time Frame: Baseline, Week 12 ]Blood pressure was measured by monitor measurements after 10 minutes resting in a supine position (3 measurements taken approximately 2 minutes apart).The changes in blood pressure were recorded and the mean of the three measurements was analyzed.
- Change From Baseline in Heart Rate to Week 12 [ Time Frame: Baseline, Week 12 ]Heart rate was measured after 10 minutes resting in a supine position (3 measurements taken approximately 2 minutes apart). The changes in heart rate were recorded and the mean of the three measurements was analyzed.
- Number of Subjects With Clinical Events (Heart Failure [HF] Hospitalization and Cardio-Vascular [CV] Mortality) [ Time Frame: Baseline until 16 weeks ]Clinical events (heart failure and mortality) were analyzed as CV death, and HF hospitalization at specified time points.
- Number of Subjects With Implantable Cardioverter Defibrillators Cardiac Resynchronization Therapy With Defibrillation (ICD/CRT-D) Therapy [ Time Frame: Baseline upto 16 weeks ]ICD / CRT with defibrillation therapy (CRT-D) included previous appropriate interventions such as shocks or anti-tachycardic pacing (ATP) when diagnostic of sustained ventricular tachycardias in pre defined rapid zone.
- Number of Subjects With Treatment-Emergent Adverse Events [ Time Frame: From the start of study treatment upto 5 days after the last dose of study drug ]An adverse event (AE) was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; and another medically important serious event as judged by the investigator. AEs are considered to be treatment-emergent if they have started or worsened after first application of study drug up to 5 days after end of treatment with study drug.
- Change in Biomarkers From Baseline to Week 12: Osteopontin (ng/mL) [ Time Frame: Baseline, Week 12 ]
- Change in Biomarkers From Baseline to Week 12: TIMP-4 (pg/mL) [ Time Frame: Baseline, Week 12 ]TIMP-4: tissue inhibitor of matrix metalloproteinases 4
- Change in Biomarkers From Baseline to Week 12: cGMP (Pmol/mL) [ Time Frame: Baseline, Week 12 ]cGMP: cyclic guanosine monophosphate
- Change in Biomarkers From Baseline to Week 12: PIIINP (mcg/L) [ Time Frame: Baseline, Week 12 ]PIIINP: pro-collagen III N-terminal peptide
- Change in Biomarkers From Baseline to Week 12: GDF-15 (pg/mL) [ Time Frame: Baseline, Week 12 ]GDF-15: growth differentiation factor 15
- Change in Biomarkers From Baseline to Week 12: ST2 (pg/mL) [ Time Frame: Baseline, Week 12 ]ST2: suppression of tumorigenicity 2
- Change in Biomarkers From Baseline to Week 12: Gal-3 (μg/mL) [ Time Frame: Baseline, Week 12 ]Gal-3: Galectin-3
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Worsening chronic heart failure (WCHF) requiring hospitalization (or intravenous diuretic treatment for HF without hospitalization) with initiation of study treatment after clinical stabilization
- Left ventricular ejection fraction (LVEF) <45% by echocardiography at randomization
Exclusion Criteria:
- Intravenous inotropes at any time after hospitalization
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01951625
Locations
Show 157 study locations
Sponsors and Collaborators
Bayer
Investigators
| Study Director: | Bayer Study Director | Bayer |
Additional Information:
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Bayer |
| ClinicalTrials.gov Identifier: | NCT01951625 |
| Other Study ID Numbers: |
15371 2013-002287-11 ( EudraCT Number ) |
| First Posted: | September 26, 2013 Key Record Dates |
| Results First Posted: | March 25, 2021 |
| Last Update Posted: | March 25, 2021 |
| Last Verified: | March 2021 |
Keywords provided by Bayer:
|
Worsening Heart Failure Heart Failure with Reduced Ejection Fraction |
Additional relevant MeSH terms:
|
Heart Failure Heart Diseases Cardiovascular Diseases |